CURRICULUM VITAE
John A. Auchampach PhD
John A. Auchampach PhD
Professor
Department of Pharmacology and Toxicology
Department of Pharmacology and Toxicology
OFFICE ADDRESS: |
Medical Education Building |
8701 Watertown Plank Rd |
Milwaukee, WI 53226 |
EDUCATION: |
1983 - 1988 BS - Pharmacy, South Dakota State College of Pharmacy, Brookings, SD |
1988 - 1992 PhD - Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
1992 - 1993 Postdoctoral Fellow, Molecular Pharmacology, Upjohn Laboratories, Kalamazoo, MI |
1993 - 1995 Postdoctoral Fellow, Molecular Physiology & Biological Physics and Medicine (Cardiology), University of Virginia, Charlottesville, VA |
2015 - 2016 Leadership Training, Lubar School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI |
FACULTY APPOINTMENTS: |
1995 - 2000 Assistant Professor, Department of Medicine (Cardiology), University of Louisville, Louisville, KY |
1998 - 2001 Associate Appointment, Department of Physiology and Biophysics, University of Louisville, Louisville, KY |
1999 - 2001 Associate Appointment, Pharmacology, University of Lousville, Louisville, KY |
2000 - 2001 Associate Professor, Department of Medicine (Cardiology), University of Louisville, Louisville, KY |
2001 - 2008 Associate Professor, Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI |
2008 - Present Professor (tenure), Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI |
ADMINISTRATIVE APPOINTMENTS: |
2016 - Present Vice Chair, Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI |
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: |
2005 - 2009 Course Director - Advanced Cellular Signal Transduction, Pharmacology & Toxicology, Medical College of Wisconsin, WI |
2006 - 2022 Pharmacology & Toxicology Graduate Program Director, Pharmacology & Toxicology, Medical College of Wisconsin, WI |
2017 - 2023 M1 Medical School Course Co-Director, Principles of Drug Action, Pharmacology & Toxicology, Medical College of Wisconsin, WI |
2024 - Present Graduate Course Director - Introduction to Pharmacology (Interdisciplinary Program in Biomedical Sciences), Pharmacology & Toxicology, Medical College of Wisconsin |
RESEARCH ADMINISTRATIVE APPOINTMENTS: |
2003 - 2007 Confocal Core Facility Director, Cardiovascular Center, Medical College of Wisconsin, WI |
2006 - 2019 Ultrasound Imaging and Rodent Physiology Core Director, Cardiovascular Center, Medical College of Wisconsin, WI |
2018 - Present Cardiac Biology and Heart Failure Affinity Group Co-Leader, Cardiovascular Center, Medical College of Wisconsin, WI |
2019 - Present Shared Ultrasound Small Animal Imaging Facility, Pharmacology & Toxicology, Medical College of Wisconsin, WI |
AWARDS AND HONORS: |
1991 Research Travel Award, International Society for Heart Research |
1991 - 1992 Predoctoral Fellowship, American Heart Association - Wisconsin Affiliate |
1992 Young Investigator Travel Award, International Society for Heart Research |
1992 Outstanding Dissertation Award, Friends of MCW, Medical College of Wisconsin |
1993 - 1995 National Research Service Award, National Institutes of Health |
1999 Extramural Funding Award, Jewish Hospital Research Foundation, Louisville, KY |
2006 Outstanding Teacher Award, Graduate Student Association, Medical College of Wisconsin |
2009 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2010 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2011 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2011 Top Reviewer, Circulation Research - published by the American Heart Association |
2013 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2014 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2015 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2016 Outstanding Graduate School Educator, Medical College of Wisconsin |
2016 Therapeutic Accelerator Program Award Winner, Medical College of Wisconsin |
2017 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2018 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2019 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2020 Outstanding Medical Student Teacher, Medical College of Wisconsin |
2021 Therapeutic Accelerator Program Award winner, Medical College of Wisconsin |
2022 Outstanding Medical Student Teacher, Medical College of Wisconsin |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
1990 - Present American Heart Association (Member) |
1990 - 2001 International Society for Heart Research (Member) |
1996 - Present American Society of Pharmacology and Experimental Therapeutics (Member) |
1997 - Present Fellow of the American Heart Association (Elected Fellow) |
2007 - 2009 Faculty of 1000 Biology (Member) |
2021 - Present Medical College of Wisconsin Society of Teaching Scholars (Elected Member) |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Editorial Board |
1997 - 2016 American Journal of Physiology |
2007 - Present Journal of Pharmacology and Experimental Therapeutics |
2007 - Present Inflammation |
2011 - 2019 Circulation Research |
Journal Review |
Microcirculation |
Basic Research in Cardiology |
FASEB Journal |
Inflammation |
Journal of Cellular Biochemistry |
Molecular Pharmacology |
Circulation |
American Journal of Physiology |
British Journal of Pharmacology |
Cardiovascular Research |
Hypertension |
Journal of Molecular and Cellular Cardiology |
Journal of Pharmacology and Experimental Therapeutics |
Biochemical Pharmacology |
Circulation Research |
Proceedings of the National Academy of Sciences US |
Journal of Nanobiotechnology |
PLoS ONE |
Journal of Molecular Medicine |
Nature |
Purinergic Signalling |
Journal of Biological Chemistry |
Journal of Clinical Investigation |
Diabetes |
JCI Insight |
Anesthesiology |
Journal of Cardiovascular Pharmacology |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
2003 - 2005 Member, Board of Directors, American Heart Association Metro Milwaukee |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
1998 - 2002 Grant Reviewer, NIH Multidisciplinary Sciences Special Emphasis Panel, Surgery, Radiology, and Bioengineering |
1998 - 2000 Member, Great America One Study Section, American Heart Association |
2004 - 2006 Member, Molecular Signaling 2 Study Section, American Heart Association |
2004 - 2005 Grant Reviewer, External Research Grant Program, Philip Morris |
2005 - 2021 Ad Hoc Reviewer, Myocardial Ischemia and Metabolism Study Section, National Heart Lung and Blood Institute |
2006 - 2022 Committee Member, Cardiovacular Pharmacology Division Program Committee, American Society for Pharmacology and Experimental Therapeutics |
2007 - 2009 External Advisory Committee Member, Center for Biomedical Research Excellence (COBRE) Program External Review Committee Member, University of Nevada, Reno (Chloride Channel Function and Role in Cardiovascular Disease), National heart Lung and Blood Institute |
2008 - Present Ad Hoc Reviewer, SBIR/STTR Integrated Review Group, National Heart Lung and Blood Institute |
2009 Ad Hoc Reviewer, Special Emphasis Panel ZRG1 CVRS-B (58) R and ZRG1 CVRS-B (53), National Heart Lung and Blood Institute |
2013 - 2016 Protocol Review and Monitoring Committee Member, Preclinical Consortium to Facilitate Translation of Cardioprotective Strategies, National Heart Lung and Blood Institute |
2023 - Present Committee member, Catalyze Product Definition Special Emphasis Panel, National Heart Lung and Blood Institute |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
International |
XIVth Congress of the European Society of Cardiology, Barcelona, Spain, 1992 |
2nd Winterpanel in Cardiology, Zermatt, Switzerland, 1993 |
6th International Symposium on Adenosine and Adenine Nucleotides, Milan, Italy, 1998 |
Purines 2000, Madrid, Spain, 2000 |
7th International Symposium on Adenosine and Adenine Nucleotides, Gold Coast, Australia, 2002 |
34th International Narcotics Research Conference, Perpignan, France, 2003 |
8th International Symposium on Adenosine and Adenine Nucleotides, Ferrara, Italy, 2006 |
Purines 2008, Copenhagen, Denmark, 2008 |
Purines 2014, Bonn, Germany, 2014 |
Keystone Symposia - Purinergic Signaling, Vancouver, Can, 2016 |
Purines 2018, Milan, Italy, 2018 |
National |
International Society for Heart Research, American Section, Burlington, VT, 1992 |
5th World Congress of the International Society for Adaptive Medicine, Framingham, MA, 1997 |
Cardiology Grand Rounds, University of Louisville, Louisville, KY, 1998 |
Seminar, Department of Pharmacology, University of Virginia, Charlottesville, VA, 2000 |
Seminar, Department of Pharmacology, Biogen, Inc., Boston, MA, 2000 |
International Society for Heart Research, Louisville, KY, 2000 |
Seminar, Department of Anesthesiology, University of Louisville, Louisville, KY, 2000 |
12th International Symposium on Adenosine, Chicago, IL, 2002 |
International Society for Heart Research, Mystic, CT, 2003 |
Seminar, Department of Medicine, New York University, New York, NY, 2006 |
Experimental Biology, San Francisco, CA, 2006 |
Seminar, Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA, 2007 |
Seminar, Cardiovascular Institute, Loyolla University, Chicago, IL, 2008 |
Research Presentation, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2012 |
Research Presentation, American Heart Association Scientific Sessions, Dallas, TX, 2013 |
Research Presentation, Cardiovascular Center, Ohio State University, Columbus, OH, 2016 |
Local |
Seminar, Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI, 1997 |
Seminar, Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, 2002 |
Seminar, Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 2003 |
Cardiology Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 2008 |
Meeting of the Cardiovascular Center Board of Directors, Medical College of Wisconsin, Milwaukee, WI, 2009 |
Research Presentation, First Annual Translational Symposium in Cardiovascular Sciences, Milwaukee, WI, 2009 |
"Work in Progress" seminar, Medical College of Wisconsin Cardiovascular Center, Milwaukee, WI, 2010 |
Cardiology Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 2011 |
"Work-in-Progress" seminar, Medical College of Wisconsin Cardiovascular Center, Milwaukee, WI, 2012 |
"Research-in-Progress" presentation, Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI, 2013 |
Drug Repurposing Interest Group, Medical College of Wisconsin, Milwaukee, WI, 2016 |
Cardiovascular Center Team Science Research Symposium, Medical College of Wisconsin, Milwaukee, WI, 2017 |
Hippo Signaling in Neuro and Muscular Biology, Milwaukee, WI, 2017 |
Seminar, Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 2018 |
Cardiovascular Center Team Science Research Symposium, Medical College of Wisconsin, Milwaukee, WI, 2018 |
Seminar, Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI, 2019 |
"Work-in-Progress" Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, 2022 |
Seminar, Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, 2023 |
"Work-in-Progress" Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, 2023 |
PEER REVIEWED WORKSHOPS/PRESENTATIONS: |
National |
Wang X, Wan TC, Lupton C, Harrison M, Lough JW, Auchampach JA, Tip60 depletion promotes cardiomyocyte proliferation and attenuates ischemic injury in the adult heart, American Heart Association Basic Cardiovascular Sciences Scientific Sessions, Boston, MA, 2019 |
Wang X, Wan TC, Lauth A, PAtterson M, Lough JW, Auchampach JA, Tip60 depletion in adult cardiomyocytes promotes proliferation and preserves cardiac fundtion after myocardial infarction, American Heart Association Basic Cardiovascular Sciences Scientific Sessions, virtual, 2020 |
Wang X, Lupton C, Lauth A, Wan TC, Patterson M, Auchampach JA, Lough JW, Tip60 depletion in neonatal cardiomyocytes reduces the DNA damage response and increases cell-cycle activation, American Heart Association Basic Cardiovascular Sciences Scientific Sessions, virtual, 2020 |
Wang X, Wan TC, Lauth A, Lough JW, Auchampach JA, Targeting Tip60 for heart regeneration and repair, Weinstein Cardiovascular Development and Regeneration webinar, virtual, 2021 |
Wang X, Kulik K, Wan TC, Lauth A, Lough JW, Auchampach JA, Pharmacological Targeting Tip60 for Heart Regeneration and Repair, Chicago Regional Cardiovascular Reseaerch forum, Northwestern University, 2022 |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
2000 - 2001 Member, Use of Genetic Materials Advisory Committee, University of Louisville |
2000 - 2001 Member, Animal Care and Use Committee, University of Louisville |
2003 - 2006 Member, Graduate Student Recruitment Committee - Interdisciplinary Program of Biomedical Sciences, Medical College of Wisconsin |
2003 - 2008 Member, Graduate Student Mentoring Committee - Interdisciplinary Program in Biomedical Sciences, Medical College of Wisconsin |
2004 - 2006 Member, Library Committee, Medical College of Wisconsin |
2004 - 2008 Member, Faculty Search Committee, Department of Pharmacology, Medical College of Wisconsin |
2006 - 2023 Member, Graduate Studies Council, Medical College of Wisconsin |
2006 - 2007 Member, Biomedical Resource Center Director Search Committee, Medical College of Wisconsin |
2007 - 2010 Member, Graduate Studies Council Program Evaluation Committee, Medical College of Wisconsin |
2008 - 2010 Chair, Graduate Studies Council Program Evaluation Committee, Medical College of Wisconsin |
2009 - 2010 Member, Medical Education Integration Council, Medical College of Wisconsin |
2009 - 2010 Member, Medical School Curriculum Committee - Cardiovascular/Renal/Respiratory module, Medical College of Wisconsin |
2012 - 2014 Member, Discovery Curriculum Expert Panel (Cardiovascular Unit), Medical College of Wisconsin |
2013 - 2014 Member, Inflammation and Immunology Work Group, Medical College of Wisconsin |
2014 - Present Member, Faculty Mentoring Committee, Medical College of Wisconsin |
2014 - 2015 Member, Pharmacy School Internal Advisory Committee, Medical College of Wisconsin |
2015 - 2022 Member, Graduate Program Directors Committee - Interdisciplinary Program in Biomedical Sciences, Medical College of Wisconsin |
2016 - Present Member, Cardiovascular Center Equipment Committee, Medical College of Wisconsin |
2016 - 2017 Member, Pharmacy School Faculty Search Committee, Medical College of Wisconsin |
2017 - 2018 Chair, Cardiovascular Center Postdoctoral Recruitment Committee, Medical College of Wisconsin |
2017 - 2018 Physiology Department Chair Search Committee, Medical College of Wisconsin |
07/01/2018 - Present Faculty Mentoring Committee (Michaela Patterson, PhD), Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin |
2021 - Present Member, Shool of Medicine Promotion Committee, Medical College of Wisconsin |
2022 - Present Member, Medical Education Committee, Pharmacology & Toxicology, Medical College of Wisconsin |
2022 - Present Member, Graduate Education Committee, Pharmacology & Toxicology, Medical College of Wisconsin |
2022 - Present Member, Faculty Search Committee, Program in Chemical Biology, Medical College of Wisconsin |
2023 - Present Vice Chair, School of Medicine Promotion Committee, Medical College of Wisconsin |
04/01/2024 - Present Member, Medical Science Training Program (MSTP) Mentoring Committee, Medical College of Wisconsin |
MCW TEACHING ACTIVITIES: |
Medical Student Education |
2001 - 2023 Principles of Drug Action (M1 Course): Autonomic nervous system pharmacology, neuromuscular junction blocking agents, local anesthetics, pharmacokinetics & pharmacodynamics |
2010 - 2023 Cardiovascular Unit (M2 Course): Review of Cardiac Function and Myocardial Oxygen Supply/Demand Balance; Heart Failure (Topic Leader); Ischemic Heart Disease/Acute Coronary Syndromes (Topic Leader); Cardiovascular Pharmacology Review |
2011 - 2023 Symptoms-Based Module (M2 Course): Syncope |
09/13/2022 M1 Myasthenia Gravis Pilot, MCWfusion Curriculum |
09/26/2022 M2 Atherosclerosis/Hypercholesterolemia Pilot, MCWfusion Curriculum |
10/18/2022 M1 Hypertension Pilot, MCWfusion Curriculum |
2023 - Present Heart Failure Pharmacology - MCWFusion Curricuum, Cardiovascular Block |
2023 - Present Ischemic heart Disease Pharmacology - MCWFusion Curriculum, Cardiovascular Block |
2023 - Present Cholinergic - Phase 1 MCWFusion Curriculum, Foundations Block |
2023 - Present Adrenergics - Phase 1 MCWFusion Curriculum, Foundations Block |
2023 - Present Neuromuscular Junction Blocking Agents - MCWFusion Curriculum, Musculoskeletal -Skin Block |
2023 - Present Pathophysiology of Ischemic Heart Disease - MCWFusion Curriculum, Cardiovascular Block |
2023 - Present Patient-Based Small Group Discussion Fascilitator |
2023 - Present Heart Failure Pathophysiology - MCWFusion Curriculum, Cardiovascular Block |
Graduate Student Education |
2003 - 2005 Biochemistry Course (Interdisciplinary Progam in Biomedical Sciences) - Signal transduction by cytokine receptors, enzyme-linked receptors, and integrins |
2003 - 2009 Advanced Cellular Signal Transduction Course (Pharmacology Graduate Program) - G protein-coupled receptors and G protein regulation of ion channels |
2005 - 2019 Cellular Signal Transduction Course (Interdisciplinary Program in Biomedical Sciences) - G protein-coupled receptors, heterotrimeric G proteins, signaling by cAMP |
2009 - 2019 Advanced Cellular Signal Transduction Course (Pharmacology Graduate Program) - beta adrenergic receptor blockers |
2017 - Present Fundamentals of Neuroscience (Neuroscience Graduate Program) - Autonomic Nervous System |
2019 - Present Understanding Cell Signaling Through Study of Therapeutic Drugs (Interdisciplinary Program in Biomedical Sciences) - Adrenergic Receptors |
2019 - Present Foundations in Biomedical Sciences III (Interdisciplinary Program in Biomedical Sciences) - Introduction to cellular signaling, G protein-coupled receptors, heterotrimeric G proteins |
2021 - Present Current Concepts in Cadiovascular Biology; Section Leader - Cardiac Biology and Heart Failure |
2024 - Present Course Director - Introduction to Pharmacology (Interdisciplinary Program in Biomedical Sciences) |
2024 - Present Ligand-Receptor Interactions (Interdisciplinary Program in Biomedical Sciences) |
MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Graduate Students |
PhD Committees |
1997 - 2002 Yunfei Cai, Pharmacology & Toxicology, Medical College of Wisconsin |
1997 - 2001 Ryan M. Fryer, Pharmacology & Toxicology, Medical College of Wisconsin |
1998 - 2002 Hemal Patel, Pharmacology & Toxicology, Medical College of Wisconsin |
1998 - 2003 Tamara Maier, Pharmacology & Toxicology, Medical College of Wisconsin |
1999 - 2004 Linda Ludwig, Pharmacology & Toxicology, Medical College of Wisconsin |
1999 - 2004 Wenqi Yang, Pharmacology & Toxicology, Medical College of Wisconsin |
1999 - 2004 Xinrong Lu, Pharmacology & Toxicology, Medical College of Wisconsin |
2000 - 2005 Erica J. Carrier, Pharmacology & Toxicology, Medical College of Wisconsin |
2003 - 2008 Rebecca Moyer, Microbiology and Molecular Genetics, Medical College of Wisconsin |
2004 - 2009 Leyu Shi, Pharmacology & Toxicology, Medical College of Wisconsin |
2005 - 2010 James Schuman, Microbiology and Molecular Genetics, Medical College of Wisconsin |
2005 - 2010 Jimmy Crockett, Pharmacology & Toxicology, Medical College of Wisconsin |
2005 - 2010 Eryn Hassemer, Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin |
2006 - 2010 Jamie Privratsky, Medical-Scientist Training Program, Pharmacology, Medical College of Wisconsin |
2007 - 2012 Elizabeth Ntante, Pharmacology & Toxicology, Medical College of Wisconsin |
2008 - 2012 Adam Gastonguay, Pharmacology & Toxicology, Medical College of Wisconsin |
2008 - 2011 Christopher Roberts, Medical-Scientist Training Program, Pharmacology, Medical College of Wisconsin |
2008 - 2013 Jackie Porath, Pharmacology & Toxicology, Medical College of Wisconsin |
2009 - 2014 Nathan Schuld, Pharmacology & Toxicology, Medical College of Wisconsin |
2009 - 2013 Lawan Siangjong, Pharmacology & Toxicology, Medical College of Wisconsin |
2012 - 2015 Jessica Wilson, Medical-Scientist Training Program, Pharmacology, Medical College of Wisconsin |
09/01/2013 - 2016 Mike Tanner, Pharmacology & Toxicology, Medical College of Wisconsin |
2015 - 2020 Rachel Schlaak, Pharmacology & Toxicology, Medical College of Wisconsin |
2015 - 2019 Andrew Kleist, Medical-Scientist Training Program, Biochemistry, Medical College of Wisconsin |
2016 - 2020 Michelle Storage, Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin |
2017 - 2021 Valery Lozada-Fernandez, Microbiology and Immunology, Medical College of Wisconsin |
2018 - Present Ayana Jamal, Medical-Scientist Training Program, Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin |
2019 - 2023 Olivia Koehn, Pharmacology & Toxicology, Medical College of Wisconsin |
2020 - 2024 Valeria Robleto, Biochemistry, Medical College of Wisconsin |
2020 - Present Kaelin Aikins, Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin |
2021 - Present Joseph Crecelius, Biochemistry, Medical College of Wisconsin |
PhD Students Advised |
2002 - 2006 Laura M. Kreckler, Modulation of Macrophage Cytokine Production by Adenosine, Medical College of Wisconsin |
2005 - 2009 Jordan Van Orman, Role of the Micro-Environment on Embryonic Stem Cell Cardiogenesis, Medical College of Wisconsin |
2005 - 2008 Dharini van der Hoeven, A3 Adenosine Receptor-Medicated Suppression of the Pro-Inflammatory Functions of Mouse Bone Marrow Neutrophils through Inhibition of Rac, Medical College of Wisconsin |
2006 - 2010 Jason Maas, Role of the A2B Adenosine Receptor in Cardiovascular Disease, Medical College of Wisconsin |
2008 - 2012 Lili Du, Allosteric Modulation of the A3 Adenosine Receptor, Medical College of Wisconsin |
2011 - 2015 Shraddha Nayak, Development of a novel Adora2b transgenic rat and role of A2B adenosine receptors in hypertension, Medical College of Wisconsin |
2019 - 2023 Courtney Fisher, Mechanistic Insights Into Novel A3 Adenosine Receptor Allosteric Modulators, Medical College of Wisconsin |
Postdoctoral Researchers |
2001 - 2005 Zhi-Dong (Wilson) Ge, M.D., Ph.D., Medical College of Wisconsin |
2002 - 2006 Tina C. Wan, Ph.D., Medical College of Wisconsin |
2018 - 2024 Xinrui (Sarea) Wang, Ph.D., Medical College of Wisconsin |
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Postdoctoral Researchers |
1998 - 1999 Hitoshi Takano, M.D., University of Louisville |
1999 - 2000 Eitaro Kodani, M.D., University of Louisville |
1999 - 2001 Ken Shinmura, M.D., Ph.D., University of Louisville |
PATENTS: |
2005 - Present Methods of Treating Ischemia Reperfusion Injury Using Adenosine Receptor Antagonists (U.S. Patent No. ZA200500254B). U.S. patent and Trademark Office
Inventors: Jin, Xiaowei, Auchampach, John A., Smits, Glenn J., Gross, Garrett J. |
2020 - Present Tip60 Inhibitors and Methods for Use for Cardiovascular Disease. (U.S. Patent No. 17/442,968). U.S. patent and Trademark Office
Inventors: Lough, John W., Auchampach, John A. |
2022 - Present A3 Adenosine Receptor Positive Allosteric Modulators (U.S. Patent No. 63/325,095). U.S. patent and Trademark Office
Inventors: Jacobson, Kenneth A., Fallot, Lucas B., Suresh, Raman R., Fisher, Courtney L., Auchampach John A. |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Auchampach JA, Maruyama M, Cavero I, Gross GJ (1991). The new K+ channel opener RP 52891 (Aprikalim) reduces experimental infarct size in the absence of hemodynamic changes. Journal of Pharmacology and Experimental Therapeutics 269:961-967. |
2. Gross GJ, Auchampach JA (1992). Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circulation Research 70:223-233. |
3. Auchampach JA, Maruyama M, Cavero I, Gross GJ (1992). Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 86:311-319. |
4. Auchampach JA, Grover GJ, Gross GJ (1992). Blockade of ischemic preconditioning in dogs by the novel ATP-dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovascular Research 26:1054-1062. |
5. Auchampach JA, Cavero I, Gross GJ (1992): Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. Journal of Cardiovascular Pharmacology 20:765-771. |
6. Auchampach JA, Gross GJ (1993): Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. American Journal of Physiology 33:H1327-H1336. |
7. Yao Z, Auchampach JA, Pieper GM, Gross GJ. (1993). Monophospholipid A increases catalase activity and reduces myocardial infarct size in dogs. Cardiovascular Research 27:832-838. |
8. Auchampach JA, Gross GJ (1993): Reduction in myocardial infarct size by the new potassium channel opener bimakalim. Journal of Cardiovascular Pharmacology 23:554-561. |
9. Warltier DC, Auchampach JA, Gross GJ (1993). Relationship of severity of myocardial stunning to ATP-dependent potassium channel modulation. Journal of Cardiovascular Surgery 8:279-283. |
10. Hillard CJ, Auchampach JA (1994). In vitro activation of brain protein kinase C by the cannabinoids. Biochimica et Biophysica Acta 1220:163-170. |
11. Auchampach JA, Oliver MJ, Anderson DC, Manning AM (1994). Cloning, sequence comparison, and in vivo expression of the gene encoding rat P-selectin. Gene 145:251-255. |
12. Manning AM, Auchampach JA, Drong RF, Slightom JL (1995). Cloning of the cDNA homologous to the human transforming growth factor-beta1-encoding gene. Gene 155:307-308. |
13. Griffin RL, Krzesicki RF, Fidler SF, Rosenbloom CL, Auchampach JA, Manning AM, Haas JV, Cammarata SK, Chin J, Richards IM (1995). Attenuation of oxidant-induced lung injury by 21-aminosteroids (Lazaroids): Correlation with the mRNA expression for E-selectin, P-selectin, ICAM-1, and VCAM-1. Environmental Health Perspectives 102(Suppl 10):193-200. |
14. Mizimura T, Auchampach JA, Linden J, Bruns RF, Gross GJ (1996). PD 81,723, an allosteric enhancer of the adenosine A1 receptor, lowers the threshold for ischemic preconditioning in dogs. Circulation Research 79:415-423. |
15. Auchampach JA, Rizvi A, Qiu Y, Tang X-L, Maldonado C, Teschner S, Bolli R (1997). Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circulation Research 80:800-806. |
16. Maldonado C, Qiu Y, Tang X-L, Cohen MV, Auchampach J, Bolli R (1997). Role of adenosine A1 receptors in late preconditioning against myocardial stunning in conscious rabbits. American Journal of Physiology 273:H1324-H1332. |
17. Auchampach JA, Jin X, Wan TC, Caughey G, Linden J (1997). Canine mast cell adenosine receptors: Cloning and expression of the A3 adenosine receptor and evidence that degranulation is mediated by the A2B receptor. Molecular Pharmacology 52:846-860. |
18. Auchampach JA, Maruyama M, Cavero I, Gross GJ (1998). Effect of the platelet-activating factor antagonist RP 59227 on myocardial ischemia/reperfusion injury and neutrophil activation. Basic Research in Cardiology 93:361-371. |
19. Ping P, Zhang J, Cao X. , Li RCX, Kong D, Tang X-L, Qiu Y, Manchikalapudi S, Auchampach JA, Black RG, Bolli R (1999). PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. American Journal of Physiology 276:H1468-H1481. |
20. Jordan JE, Thourani VH, Auchampach JA, Vinten-Johansen J (1999). A3 adenosine receptors: Their role in modulating neutrophil superoxide production, degranulation, adherence to coronary endothelium, and reperfusion injury. American Journal of Physiology 277:H1895-H1905. |
21. Gumina RJ, Auchampach JA, Daemmgen J, Gross GJ (2000). Na+/H+ exchange inhibition-induced cardioprotection: Role of neutrophils vs. cardiomyocytes. American Journal of Physiology 279:H1563-H1570. |
22. Takano T, Bolli R, Black RG, Jr, Kodani E, Tang XL, Yang Z, Battacharya S, Auchampach JA (2001). Activation of A1 or A3 adenosine receptors induces late preconditioning against infarction in conscious rabbits by different mechanisms. Circulation Research 88:520-528. |
23. Guo Y, Bolli R, Bao W, Wu WJ, Black RG, Murphree SS, Salvatore CA, Jacobson MA, Auchampach JA (2001). Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. Journal of Molecular and Cellular Cardiology 33:825-830. |
24. Kodani E, Bolli R, Tang XL, Auchampach JA (2001). Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor. Basic Research in Cardiology 96:487-496. |
25. Kodani E, Tang XL, Shinmura K, Auchampach JA, Bolli R (2001). Cyclooxygenase-2 does not mediate late preconditioning against infarction induced by adenosine A1 or A3 receptors. American Journal of Physiology 281:H959-H968. |
26. Black RG, Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, Bolli R, Auchampach JA (2002). Gene dosage dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circulation Research 91:165-172. |
27. Cross H, Murphy E, Black RG, Auchampach JA, Steenbergen C (2002). Overexpression of A3 adenosine receptors decreases heart rate, preserves energetics, and protects the ischemic heart. American Journal of Physiology 283:H1562-H1568. |
28. Ge ZD, Auchampach JA, Pieper GM, Gross GJ (2003) Evidence that thromboxane does not modulate infarct size using two different thromboxane receptor antagonists. Journal of Cardiovascular Pharmacology. 41: 481-488. |
29. Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ (2003) The A3 adenosine receptor agonist IB-MECA reduces ischemia-reperfusion injury in dogs. American Journal of Physiology 285:H607-H613. |
30. Ticho B, Whalley E, Gill A, Lutterodt F, Jin X, Auchampach JA, Smits G (2003). Renal effects of BG 9928, an A1 adenosine receptor antagonist, in rats and nonhuman primates. Drug Development Research 58:486-492. |
31. Fabritz L, Kirchhof P, Fortmüller L, Auchampach JA, Baba HA, Breithardt G, Neumann J, Boknik P, Schmitz W. (2004) Gene dose-dependent atrial arrhythmias, heart block and brady-cardiomyopathy in mice overexpressing A3 adenosine receptors. Cardiovascular Research 62:500-508. |
32. Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smitts G, Gross GJ. (2004) Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. Journal of Pharmacology and Experimental Therapeutics 308:846-856. |
33. Gross ER, Peart JN, Hsu AK, Auchampach JA, Gross GJ (2005). Extending the cardioprotective window by a novel opioid agonist fentanyl isothiocyanate via the phosphoinositol-3 kinase pathway. American Journal of Physiology 288:H2744-H2749. |
34. Kreckler LM, Wan TC, Ge ZD, Auchampach JA (2006). Adenosine inhibits TNF-alpha release from mouse peritoneal macrophages via A2A and A2B, but not A3 adenosine receptors. Journal of Pharmacology and Experimental Therapeutics 317:172-180. |
35. Carrier E, Auchampach JA, Hillard CJ (2006). Inhibition of the equilibrative nucleoside transporter by cannabidiol: A novel mechanism of cannabionoid immunosuppression. Proceedings of the National Academy of Sciences USA 103:7895-7900. |
36. Nelson TJ, Ge ZD, Van Orman J, Barron M, Rudy-Reil D, Hacker TM, Misra R, Duncan SA, Auchampach JA, Lough J. (2006). Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells. Anatomical Record 288A:1216-1224. |
37. Ge ZD, Peart JN, Kreckler LM, Wan TC, van der Hoeven D, Gross GJ, Jacobson MA, Auchampach JA (2006). Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methycarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. Journal of Pharmacology and Experimental Therapeutics 319:1200-1210. |
38. Wan TC, Ge ZD, Bienengraeber MW, Tampo A, Kwok WM, Tracey WR, Gross GJ, Auchampach JA (2008). The A3 adenosine receptor agonist CP-532,903 protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP sensitive potassium channel. Journal of Pharmacology and Experimental Therapeutics 324:234-243. |
39. Melman A, Gao ZG, Kumar D, Wan TC, Gizewski E, Auchampach JA, Jacobson KA. (2008) Design of (N)-Methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorganic Medicinal Chemistry Letters 18:2813-2819. |
40. van der Hoeven D, Wan TC, and Auchampach JA (2008). Activation of A3 adenosine receptors in mouse bone marrow neutrophils inhibits superoxide production and chemotaxis. Molecular Pharmacology 74:685-696. |
41. Liu GI, Auchampach JA, Hillard CJ, Zhu G, Yousufzai B, Mian S, Khan S, Khalifa Y (2008). Mediation of cannabidiol anti-inflammation in the retina by the equilibrative nucleoside transporter and the A2A adenosine receptor. Investigative Journal of Ophthalmology and Vision Science 49:5526-5531. |
42. Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE. (2009). Pharmacological characterization of A2B adenosine receptors from mouse, rabbit, and dog. Journal of Pharmacology and Experimental Therapeutics 329:2-13. |
43. Kreckler LM, Wan TC, Gizewski E, Auchampach JA (2009). Adenosine suppresses LPS-induced TNF-alpha production from murine macrophages by inhibiting gene transcription through a PKA- and EPAC-independent signaling pathway. Journal of Pharmacology and Experimental Therapeutics 331:1051-1061. |
44. Ge Z-D, Pravdic D, Kwok C, Bienengraeber MW, Pratt PF, Auchampach JA, Gross GJ, Bosnjak ZJ, Kersten JR, Warltier DC (2010). The cardioprotective effect of isofluorane postconditioning is mediated by eNOS through inhibiting mitochondrial permeability transition in mice. Anesthesiology 112:73-85. |
45. Auchampach JA, Gizewski ET, Wan TC, de Castro S, Brown GG, Jacobson KA (2010). Synthesis and pharmacological characterization of [125I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor. Biochemical Pharmacology 79:967-973. |
46. van der Hoeven D, Gizewski ET, Auchampach JA (2010). Activation of the A3 adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils. Biochemical Pharmacology 79:1667-1673. |
47. Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA (2010). A3 adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. Journal of Molecular and Cellular Cardiology 49:280-286. |
48. Maas JE, Wan TC, Figler RA, Gross GJ, Auchampach JA (2010). Evidence that the acute phase of ischemic preconditioning does not require signaling by the A2B adenosine receptor. Journal of Molecular and Cellular Cardiology 49:886-893. |
49. Xiang, S, Ge ZD, Wan TC, Auchampach JA, Gross GJ, Duan D. (2011). Characterization of a critical role of CFTR chloride channels in cardioprotection against ischemia/reperfusion injury. Act Pharmacologica Sinica 32:824-833. |
50. van der Hoeven D, Gizewski E, Wan TC, Auchampach JA (2011). A role for the low-affinity A2B adenosine receptor in suppressing superoxide production by neutrophils. Journal of Pharmacology and Experimental Therapeutics 338:1004-1012. |
51. Fisher JB, Kim MS, Blinka S, Ge ZD, Wan TC, Duris C, Christian D, Twaroski K, North P, Auchampach JA, Lough J (2012) Stress-induced cell-cycle activation in Tip60 haploinsufficient adult cadiomyocytes. PLos One 72:e31569 |
52. Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. J Pharmacol Exp Ther. 2012 Jan;340(1):210-7. PMCID: PMC3251031 |
53. Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, Auchampach JA. Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. BMC Pharmacol. 2011 Oct 31;11:11. PMCID: PMC3247180 |
54. Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA, Jacobson KA. Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem. 2012 May 24;55(10):4847-60. PMCID: PMC3371665 |
55. Chandrasekera PC, Wan TC, Gizewski ET, Auchampach JA, Lasley RD. Adenosine A1 receptors heterodimerize with β1- and β2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling. Cell Signal. 2013 Apr;25(4):736-42. PMCID: PMC3896953 |
56. Kozma E, Gizewski ET, Tosh DK, Squarcialupi L, Auchampach JA, Jacobson KA (2013). Characterization by flow cytometry of fluorescent, selective agonist probes of the A3 adenosine receptor. Biochemical Pharmacology 85:1171-1181. |
57. Ntantie E, Gonyo P, Lorimer EL, Hauser AD, Schuld N, McAllister D, Kalyanaraman B, Dwinell MB, Auchampach JA, Williams CL. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci Signal. 2013 May 28;6(277):ra39. PMCID: PMC4278376 |
58. Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA. Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. J Med Chem. 2013 Jul 25;56(14):5949-63. PMCID: PMC3858399 |
59. Kriska T, Cepura C, Siangjong L, Wan TC, Auchampach JA, Shaish A, Haratz D, Kumar G, Falck JR, Gauthier KM, Campbell WB. Effect of human 15-lipoxygenase-1 metabolites on vascular function in mouse mesenteric arteries and hearts. Prostaglandins Other Lipid Mediat. 2013 Oct;106:8-15. PMCID: PMC3844054 |
60. Lakshmikanthan S, Zieba BJ, Ge ZD, Momotani K, Zheng X, Lund H, Artamonov MV, Maas JE, Szabo A, Zhang DX, Auchampach JA, Mattson DL, Somlyo AV, Chrzanowska-Wodnicka M. Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure. Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1486-94. PMCID: PMC4224284 |
61. Tosh DK, Finley A, Paoletta S, Moss SM, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA. In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. J Med Chem. 2014 Dec 11;57(23):9901-14. PMCID: PMC4266358 |
62. Tosh DK, Crane S, Chen Z, Paoletta S, Gao ZG, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA. Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy. ACS Med Chem Lett. 2015 Jul 09;6(7):804-8. PMCID: PMC4499829 |
63. Tosh DK, Paoletta S, Chen Z, Crane S, Lloyd J, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA. Structure-Based Design, Synthesis by Click Chemistry and <i>in Vivo</i> Activity of Highly Selective A<sub>3</sub> Adenosine Receptor Agonists. Medchemcomm. 2015;6:555-563. PMCID: PMC4517612 |
64. Nayak S, Khan MA, Wan TC, Pei H, Linden J, Dwinell MR, Geurts AM, Imig JD, Auchampach JA. Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. Purinergic Signal. 2015 Dec;11(4):519-31. PMCID: PMC4648794 |
65. Tosh DK, Ciancetta A, Warnick E, O'Connor R, Chen Z, Gizewski E, Crane S, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA. Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists. J Med Chem. 2016 Apr 14;59(7):3249-63. PMCID: PMC4970510 |
66. Carlin JL, Jain S, Gizewski E, Wan TC, Tosh DK, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML. Hypothermia in mouse is caused by adenosine A<sub>1</sub> and A<sub>3</sub> receptor agonists and AMP via three distinct mechanisms. Neuropharmacology. 2017 Mar 01;114:101-113. PMCID: PMC5183552 |
67. Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA. Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem. 2017 Apr 13;60(7):3109-3123. PMCID: PMC5501184 |
68. Densmore JC, Schaid TR, Jeziorczak PM, Medhora M, Audi S, Nayak S, Auchampach J, Dwinell MR, Geurts AM, Jacobs ER. Lung injury pathways: Adenosine receptor 2B signaling limits development of ischemic bronchiolitis obliterans organizing pneumonia. Exp Lung Res. 2017 Feb;43(1):38-48. PMCID: PMC5831175 |
69. Fisher JB, Horst A, Wan T, Kim MS, Auchampach J, Lough J. Depletion of Tip60 from In Vivo Cardiomyocytes Increases Myocyte Density, Followed by Cardiac Dysfunction, Myocyte Fallout and Lethality. PLoS One. 2016;11(10):e0164855. PMCID: PMC5074524 |
70. Du L, Gao ZG, Paoletta S, Wan TC, Gizewski ET, Barbour S, van Veldhoven JPD, IJzerman AP, Jacobson KA, Auchampach JA. Species differences and mechanism of action of A<sub>3</sub> adenosine receptor allosteric modulators. Purinergic Signal. 2018 Mar;14(1):59-71. PMCID: PMC5842153 |
71. Duroux R, Ciancetta A, Mannes P, Yu J, Boyapati S, Gizewski E, Yous S, Ciruela F, Auchampach JA, Gao ZG, Jacobson KA. Bitopic fluorescent antagonists of the A<sub>2A</sub> adenosine receptor based on pyrazolo[4,3-<i>e</i>][1,2,4]triazolo[1,5-<i>c</i>]pyrimidin-5-amine functionalized congeners. Medchemcomm. 2017 Aug 01;8(8):1659-1667. PMCID: PMC5729930 |
72. Carlin JL, Jain S, Duroux R, Suresh RR, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML. Activation of adenosine A<sub>2A</sub> or A<sub>2B</sub> receptors causes hypothermia in mice. Neuropharmacology. 2018 Sep 01;139:268-278. PMCID: PMC6067974 |
73. Wodsedalek DJ, Paddock SJ, Wan TC, Auchampach JA, Kenarsary A, Tsaih SW, Flister MJ, O'Meara CC. IL-13 promotes in vivo neonatal cardiomyocyte cell cycle activity and heart regeneration. Am J Physiol Heart Circ Physiol. 2019 Jan 01;316(1):H24-H34. |
74. Tosh DK, Ciancetta A, Mannes P, Warnick E, Janowsky A, Eshleman AJ, Gizewski E, Brust TF, Bohn LM, Auchampach JA, Gao ZG, Jacobson KA. Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. ACS Omega. 2018 Oct 31;3(10):12658-12678. PMCID: PMC6210068 |
75. Yu J, Mannes P, Jung YH, Ciancetta A, Bitant A, Lieberman DI, Khaznadar S, Auchampach JA, Gao ZG, Jacobson KA. Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A<sub>3</sub> adenosine receptor antagonists. Medchemcomm. 2018 Nov 01;9(11):1920-1932. PMCID: PMC6256369 |
76. Tosh DK, Rao H, Bitant A, Salmaso V, Mannes P, Lieberman DI, Vaughan KL, Mattison JA, Rothwell AC, Auchampach JA, Ciancetta A, Liu N, Cui Z, Gao ZG, Reitman ML, Gavrilova O, Jacobson KA. Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series. J Med Chem. 2019 Feb 14;62(3):1502-1522. PMCID: PMC6467784 |
77. Wan TC, Tampo A, Kwok WM, Auchampach JA. Ability of CP-532,903 to protect mouse hearts from ischemia/reperfusion injury is dependent on expression of A<sub>3</sub> adenosine receptors in cardiomyoyctes. Biochem Pharmacol. 2019 May;163:21-31. PMCID: PMC6470012 |
78. Tosh DK, Salmaso V, Rao H, Bitant A, Fisher CL, Lieberman DI, Vorbrüggen H, Reitman ML, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA. Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A<sub>3</sub> Adenosine Receptors: Affinity Enhancement by <i>N</i><sup>6</sup>-(2-Phenylethyl) Substitution. J Med Chem. 2020 Apr 23;63(8):4334-4348. PMCID: PMC7443318 |
79. Flinn MA, Otten C, Brandt ZJ, Bostrom JR, Kenarsary A, Wan TC, Auchampach JA, Abdelilah-Seyfried S, O'Meara CC, Link BA. Llgl1 regulates zebrafish cardiac development by mediating Yap stability in cardiomyocytes. Development. 2020 Aug 25;147(16). PMCID: PMC7473637 |
80. Tosh DK, Salmaso V, Rao H, Campbell R, Bitant A, Gao ZG, Auchampach JA, Jacobson KA. Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A<sub>3</sub> Receptor Agonists. ACS Med Chem Lett. 2020 Oct 08;11(10):1935-1941. PMCID: PMC7549272 |
81. Wang X, Lauth A, Wan TC, Lough JW, Auchampach JA. <i>Myh6</i>-driven Cre recombinase activates the DNA damage response and the cell cycle in the myocardium in the absence of loxP sites. Dis Model Mech. 2020 Dec 18;13(12). PMCID: PMC7758623 |
82. Wang X, Lupton C, Lauth A, Wan TC, Foster P, Patterson M, Auchampach JA, Lough JW. Evidence that the acetyltransferase Tip60 induces the DNA damage response and cell-cycle arrest in neonatal cardiomyocytes. J Mol Cell Cardiol. 2021 Jun;155:88-98. PMCID: PMC8154663 |
83. Wang X, Wan TC, Lauth A, Purdy AL, Kulik KR, Patterson M, Lough JW, Auchampach JA. Conditional depletion of the acetyltransferase Tip60 protects against the damaging effects of myocardial infarction. J Mol Cell Cardiol. 2022 Feb;163:9-19. PMCID: PMC8816866 |
84. Tosh DK, Salmaso V, Campbell RG, Rao H, Bitant A, Pottie E, Stove CP, Liu N, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA. A<sub>3</sub> adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity. Eur J Med Chem. 2022 Jan 15;228:113983. PMCID: PMC8865922 |
85. Auchampach J, Han L, Huang GN, Kühn B, Lough JW, O'Meara CC, Payumo AY, Rosenthal NA, Sucov HM, Yutzey KE, Patterson M. Measuring cardiomyocyte cell-cycle activity and proliferation in the age of heart regeneration. Am J Physiol Heart Circ Physiol. 2022 Apr 01;322(4):H579-H596. PMCID: PMC8934681 |
86. Fisher CL, Fallot LB, Wan TC, Keyes RF, Suresh RR, Rothwell AC, Gao ZG, McCorvy JD, Smith BC, Jacobson KA, Auchampach JA. Characterization of Dual-Acting A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gα<sub>i3</sub> and Gα<sub>oA</sub> Isoprotein Activation. ACS Pharmacol Transl Sci. 2022 Aug 12;5(8):625-641. PMCID: PMC9380209 |
87. Wang X, Wan TC, Kulik KR, Lauth A, Smith BC, Lough JW, Auchampach JA. Pharmacological inhibition of the acetyltransferase Tip60 mitigates myocardial infarction injury. Dis Model Mech. 2023 May 01;16(5). PMCID: PMC9672930 |
88. Fallot LB, Suresh RR, Fisher CL, Salmaso V, O'Connor RD, Kaufman N, Gao ZG, Auchampach JA, Jacobson KA. Structure-Activity Studies of 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators. J Med Chem. 2022 Nov 24;65(22):15238-15262. PMCID: PMC10354740 |
89. Tosh DK, Fisher CL, Salmaso V, Wan TC, Campbell RG, Chen E, Gao ZG, Auchampach JA, Jacobson KA. First Potent Macrocyclic A<inf>3</inf> Adenosine Receptor Agonists Reveal G-Protein and β-Arrestin2 Signaling Preferences ACS Pharmacology and Translational Science. 2023. |
90. Tosh DK, Fisher CL, Salmaso V, Wan TC, Campbell RG, Chen E, Gao ZG, Auchampach JA, Jacobson KA. First Potent Macrocyclic A<sub>3</sub> Adenosine Receptor Agonists Reveal G-Protein and β-Arrestin2 Signaling Preferences. ACS Pharmacol Transl Sci. 2023 Sep 08;6(9):1288-1305. PMCID: PMC10496144 |
91. Fisher CL, Pavan M, Salmaso V, Keyes RF, Wan TC, Pradhan B, Gao ZG, Smith BC, Jacobson KA, Auchampach JA. Extrahelical Binding Site for a 1<i>H</i>-Imidazo[4,5-c]quinolin-4-amine A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulator on Helix 8 and Distal Portions of Transmembrane Domains 1 and 7. Mol Pharmacol. 2024 Feb 15;105(3):213-223. PMCID: PMC10877738 |
92. Pradham B, Fisher CL, Pavan M, Salmaso V, Wan TC, Keyes RF, Rollison N, Suresh RR, Kumar TS, Gao ZG, Smith BC, Auchampach JA*, Jacobson KA*. Lipid trolling to optimize A3 adenosine receptor positive allosteric modulators. Journal of Medicinal Chemistry (under review; *Co-corresponding authors) |
93. Wang X, Kulik K, Wan TC, Lough JW, Auchampach JA. Histone H2A.Z Deacetylation and Dedifferentiation in Infarcted/Tip60-depleted Cardiomyocytes. bioRxiv. 2025 Jan 02. PMCID: PMC10802610 |
94. Tosh DK, Pavan M, Cronin C, Pottie E, Wan TC, Chen E, Lewicki SA, Campbell RG, Gao ZG, Auchampach JA, Stove CP, Liang BT, Jacobson KA. 2-Substituted (N)-Methanocarba A<inf>3</inf> Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization ACS Pharmacology and Translational Science. 2024. |
95. Pradhan B, Pavan M, Fisher CL, Salmaso V, Wan TC, Keyes RF, Rollison N, Suresh RR, Kumar TS, Gao ZG, Smith BC, Auchampach JA, Jacobson KA. Lipid Trolling to Optimize A<sub>3</sub> Adenosine Receptor-Positive Allosteric Modulators (PAMs). J Med Chem. 2024 Jul 25;67(14):12221-12247. PMCID: PMC11636968 |
96. Tosh DK, Pavan M, Cronin C, Pottie E, Wan TC, Chen E, Lewicki SA, Campbell RG, Gao ZG, Auchampach JA, Stove CP, Liang BT, Jacobson KA. 2-Substituted (N)-Methanocarba A<sub>3</sub> Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization. ACS Pharmacol Transl Sci. 2024 Jul 12;7(7):2154-2173. PMCID: PMC11249627 |
Books, Chapters, and Reviews |
1. Gross GJ, Auchampach JA, Maruyama M, Warltier DC, Pieper GM (1992). Cardioprotective effects of nicorandil. Journal of Cardiovascular Pharmacology 20:522-528. |
2. Auchampach JA, Maruyama M, Gross GJ (1994). Cardioprotective actions of potassium channel openers. European Heart Journal 15(Suppl C):89-94. |
3. Gross GJ, Auchampach JA (1992). Role of ATP-dependent potassium channels in myocardial ischemia. Cardiovascular Research 26:1011-1016. |
4. Gross GJ, Yao Z, Pieper GM, Auchampach JA (1993). The ATP-regulated potassium channel in ischemia-reperfusion injury. Annals of the New York Academy of Sciences 723:71-81. |
5. Auchampach JA, Gross GJ (1993). Anti-ischemic actions of potassium channel openers in experimental myocardial ischemia/reperfusion injury. European Heart Journal 14(Suppl B):10-15. |
6. Gross GJ, Yao Z, Auchampach JA (1994). Role of ATP-sensitive potassium channels in ischemic preconditioning. In: Ischemic preconditioning: The concept of endogenous cardioprotection. Ed. Przyklenk K, Kloner R, and Yellon D. Kluwer Academic Publishers, New York, NY. pp. 125-135. |
7. Gross GJ, Yao Z, Auchampach JA (1996). KATP Channels, adenosine receptors, and ischemic preconditioning. In: Purines and Myocardial Protection. Ed. Adb-Elfattah AA, Kluwer Academic Publishers, New York, NY, pp. 459-468. |
8. Luthin D, Auchampach JA, Linden J (1996). Adenosine receptors. In: Biomembranes Vol. 2-Rhodopsins and G-protein linked receptors. Ed. Lee AG. JAI Press Inc, Greenwich, CN. pp. 321-347. |
9. Linden J, Auchampach JA, Jin X, Figler RA (1998). The structure and function of A1 and A2B adenosine receptors. Life Sciences 62:1519-1524. |
10. Auchampach JA, Tang X-L, Qiu Y, Ping P, Bolli R (1998). Late preconditioning against myocardial stunning: Pathogenesis and pathophysiology. In: Advances in Organ Biology, Vol. 6. Ed. Das D. JA1 Press, Greenwich, CN. pp 121-134. |
11. Auchampach JA, Bolli R (1999). Adenosine receptor subtypes in the heart: Therapeutic opportunities and challenges. American Journal of Physiology 276:H1113-H1116. |
12. Pelleg A, Vassort G, Auchampach JA. (2000). ATP and adenosine signal transductions in the cardiovascular system. In: Heart Physiology and Pathophysiology, Fourth Edition. Ed. Sperelakis N, Kurachi Y, Terzic A, Cohen M. Academic Press, San Diego, CA., pp. 633-656. |
13. Fryer RM, Auchampach JA, Gross GJ (2002). Therapeutic Receptor Targets of Ischemic Preconditioning. Cardiovascular Research 55:520-525. |
14. Auchampach JA, Gross GJ (2007). Reperfusion injury: Does it exist? Journal of Molecular and Cellular Cardiology. 42: 12-18. |
15. Auchampach JA (2007). Adenosine receptors and angiogenesis. Circulation Research. 101: 1075-1077. |
16. Headrick JP, Peart JN, Kwok WM, Auchampach JA (2010). Cardiovascular Biology of the A3 Adenosine Receptor. In: A3 Adenosine Receptors in Research and Therapy, from Experimental Pharmacology to Clinical Utility, Vol. 1. Ed. Borea PA. Springer SBM (Netherlands), pp. 189-208. |
17. Gao ZG, Auchampach JA, Jacobson KA. Species dependence of A<sub>3</sub> adenosine receptor pharmacology and function. Purinergic Signal. 2023 Sep;19(3):523-550. PMCID: PMC9763816 |
